Physician profile
Michael Haddow
NPI 1013039098
$6,828.06
in general payments reported to CMS, 2019-2025
13 companies · $902 in 2025
The $902 reported for 2025 was more than what 87% of Periodontics providers received nationally (typical 2025 total: $111).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $751 · 2021: $2,400 · 2022: $853 · 2023: $552 · 2024: $617 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Education: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.22 |
| Education | $775.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $3,549.38 | 2019-2022 | |
| Zimvie INC. | $1,828.23 | 2022-2025 | |
| Straumann USA LLC | $251.02 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $240.92 | 2025 | Pyrukynd |
| Salvin Dental Specialties, INC. | $230.97 | 2019 | |
| Geistlich Pharma, North America, INC. | $210.25 | 2019-2024 | Geistlich Bio-Gide |
| Glaxosmithkline, LLC. | $124.84 | 2025 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $124.74 | 2025 | Breztri |
| Teva Pharmaceuticals USA, INC. | $121.35 | 2025 | Uzedy |
| Orapharma, A Division of Bausch Health US, LLC | $97.07 | 2024 | Arestin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.67 | 2024 | |
| Nobel Biocare USA | $15.97 | 2023 | Nobelactive |
| Dentsply Sirona INC | $13.65 | 2025 | Cavitron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Haddow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.